Trius Therapeutics Wins $28 Million Federal Contract
Trius Therapeutics, a developer of antibacterial drugs, has received a $28 million contract from the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health, for the development of novel antibiotics directed against multiple Gram-negative bacterial pathogens.
Under the five-year contract, Trius will develop novel drugs targeting bacterial DNA gyrase and topoisomerase IV, with the aim of optimizing these drugs for activity against relevant biodefense pathogens such as Yersinia pestis, Francisella tularensis and Burkholderia pseudomallei.
Trius will collaborate with investigators at Lawrence Livermore National Laboratories to identify and optimize lead molecules and to test these compounds for activity against Gram-negative biodefense pathogens.
Federal funding will be provided for this project by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Department of Health and Human Services. The project will be 100% federally funded in the amount of $28 million.
Jeffrey Stein, CEO of Trius, said: “We will focus our efforts to address the NIAID mission to develop new medical countermeasures against biological agents most likely to be used in a terror attack on civilian populations. Trius offers a novel approach to develop effective new drugs to treat infections caused by such deadly pathogens.”